Antunes Murillo de Oliveira, Scudeler Thiago Luis
Instituto do Coração (InCor), Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
Universidade São Francisco (USF), Bragança Paulista, São Paulo, Brazil.
Int J Cardiol Heart Vasc. 2020 Mar 25;27:100503. doi: 10.1016/j.ijcha.2020.100503. eCollection 2020 Apr.
Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease. The disease is characterized by marked variability in morphological expression and natural history, ranging from asymptomatic to heart failure or sudden cardiac death. Left ventricular hypertrophy and abnormal ventricular configuration result in dynamic left ventricular outflow obstruction in most patients. The goal of pharmacological therapy in HCM is to alleviate the symptoms, and it includes pharmacotherapies and septal reduction therapies. In this review, we summarize the relevant clinical issues and treatment options of HCM.
肥厚型心肌病(HCM)是最常见的遗传性心脏病。该疾病的特征是形态学表现和自然病史存在显著差异,范围从无症状到心力衰竭或心源性猝死。左心室肥厚和异常的心室形态在大多数患者中导致动态左心室流出道梗阻。HCM的药物治疗目标是缓解症状,包括药物治疗和减隔治疗。在本综述中,我们总结了HCM的相关临床问题和治疗选择。